The Russian anti-tumor drug "AntionkoRAN-M" has successfully passed the first phase of clinical trials.
The developers of the Russian gene therapy drug AntionkoRAN-M have completed the first phase of clinical trials, confirming its safety. This was reported by the press service of the Russian "National Technology Initiative" platform. Notably, "AntionkoRAN-M" is the first Russian non-viral gene therapy drug against cancer, which has been licensed by the Ministry of Health for clinical testing. The trials included 13 patients aged between 30 to 78 years. The drug was developed by the "Russian Biotechnology" company.
Maxim Kuksharov, the founder of Russian Biotechnology, stated, "The primary goal of the first phase of clinical trials is to confirm the safety of the drugs for patients. During the study, no serious adverse phenomena were found associated with the use of AntionkoRAN-M in any of the patients. Additionally, a treatment response was observed in several patients, despite having undergone numerous treatment programs and exhausting all possible treatment methods." The active part of the first phase of the studies lasted for two years. During this time, the drug developers confirmed its safety, selected the required dosing for treatment and its sequence, and evaluated the drug's distribution in the human body. Patients with tumors were diagnosed with conditions such as skin cancer, breast cancer, sarcoma, and others.
Kuksharov added, "All these classifications among patients need new types of treatments since doctors have a limited number of tools to combat them, and we have two new phases of research ahead before we can launch the drug into the market." In the subsequent phases of the trials, scientists will assess the drug's effectiveness against different types of tumors, as well as its impact on a broader group of patients. The company has submitted a package of documents to the Russian Ministry of Health to obtain permission to conduct second-phase clinical trials.
